Searched for
CIPLA SALES GROWTH
Cipla in no hurry to launch semaglutide as Yurpeak gains tractionCipla is focusing on its tirzepatide brand Yurpeak in India's obesity market. Yurpeak has become the second largest GLP-1 product since its...- Stocks in news: Infosys, IndusInd Bank, Eternal, Adani Green, Dr Reddy'sIndian markets experienced a decline on Wednesday due to global and geopolitical concerns. IndusInd Bank reported a significant profit incr...
- Domestic formulations, chronic therapies to drive Pharma Q1; US generics remain dragThe healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsOil is crucial for every part of the Indian economy: From government to consumer, its price impacts spending by every stakeholder. So, till...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsOver the next few trading sessions, the direction of indices like the Nifty and Sensex will be determined by news on ceasefire violations a...
- Wegovy, Ozempic regain weight as Indian generics fall behindNovo Nordisk's weight-loss drugs are regaining market share from Indian generics. Innovator brands show steady month-on-month sales growth,...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 25%As the market makes an attempt to move upward, there is a clear preference for sectors that are focused on the domestic market. Given this,...
- These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsIn just a few days, the Q1 earnings season for FY27 will start. But before that will come the season of business updates. And that needs to...
- For low risk-takers: 5 large-caps from different sectors with an upside potential of up to 31%Now, there is nothing wrong with being bullish, because it has always paid to be bullish. Yes, one might argue that it has not paid in the ...
- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- Strong revenue growth fails to shield India Inc margins in March quarterCorporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...
- Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap playsIndian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...
- Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked targetCipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despit...
- Cipla Q4 profit drops 55% to Rs 555 crore; board recommends Rs 13 dividendCipla's fourth-quarter net profit saw a significant drop of 55 percent year-on-year. For the full financial year, the company's profit also...
- TVS Motor Q4 Results: Cons PAT grows 19% YoY to Rs 772 crore as revenue jumps 30%TVS Motor Q4 Results: TVS Motor posted a strong Q4FY26 with net profit up 19% to Rs 772 crore and revenue rising 30% to Rs 15,053 crore. Ov...
- Cipla Q4 Results Preview: Profit may rise up to 71% YoY on healthy operationsCipla Q4 Results Preview: As per the combined projections of four brokerages, there's a possibility of the net profit for the fourth quarte...
- Cipla aims to reach $1bn India sales through tie-upsCipla has stepped up launch plans in areas like respiratory, dermatology, cardiovascular and urology, which will help speed up its India gr...
- Indiabulls Securities downgrades Cipla to 'Hold'Indiabulls Securities downgrades Cipla to ‘Hold’ with a fair value of Rs 246.
Load More
